Preferred Label : sotrovimab;
Obsolete resource : false;
MeSH hyponym : GSK4182136; VIR7831;
UNII : 1MTK0BPN8V;
Origin ID : C000711967;
UMLS CUI : C5433947;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also (suggested by CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/sotrovimab-500-mg-solution-a-diluer-pour-perfusion-intraveineuse-xevudy
2024
false
false
false
France
French
infusions, intravenous
drug information
adult
adolescent
COVID-19
sotrovimab
sotrovimab
---
https://www.has-sante.fr/jcms/p_3411520/fr/xevudy-sotrovimab-covid-19
2023
false
false
false
France
adult
adolescent
infusions, intravenous
sotrovimab
evaluation of the transparency committee
COVID-19
sotrovimab
---
https://pgtmsite.files.wordpress.com/2024/01/ad_covid-ambulatoire-adulte_mod_vf-1.pdf
2023
Canada
drug information
adult
Description
Ambulatory
COVID-19
sotrovimab
quebec
Doctor of Medicine
Secondary Outcome Measure
OMD Gene
Osteomodulin
Legal Adult
Analyzed
Sotrovimab
adulthood
Remdesivir
Volar
Poultice Dosage Form Category
GDC Metastasis at Diagnosis Terminology
Ambulatory Care Facility
Veklury
Poultice
remdesivir
Identifier
has patient
Maryland
outpatients
COVID-19 Infection
hospitals, university
Usage
remdesivir
Volt
Analysis
sotrovimab
Moldova, Republic of
GDC Method of Diagnosis Terminology
Patient
disease
---
https://pgtmsite.files.wordpress.com/2024/01/ad_covid-ambulatoire-pediatrie_vf2_20230405.pdf
https://pgtmsite.files.wordpress.com/2024/01/poster_covid-adulte-et-ped_apes_-2023_final-1.pdf
2023
false
false
false
Canada
antibodies, monoclonal, humanized
antibodies, neutralizing
alanine
adenosine monophosphate
ribonucleotides
pediatrics
alanine
adenosine monophosphate
ribonucleotides
guidelines for drug use
remdesivir
sotrovimab
outpatients
hospitals, university
COVID-19
quebec
---
https://www.has-sante.fr/jcms/p_3344400/fr/xevudy-sotrovimab-covid-19
2022
false
false
false
false
false
France
French
evaluation of the transparency committee
COVID-19
sotrovimab
sotrovimab
xevudy
registries
---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1229
2022
false
false
false
France
COVID-19
scientific and technical information
mail
sotrovimab
sotrovimab
postal service
---
https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
sotrovimab
sotrovimab
sotrovimab
COVID-19
adult
adolescent
drug approval
europe
infusions, intravenous
spike protein, SARS-CoV-2
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
---
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2
Omicron BA.2 Subvariant
https://recalls-rappels.canada.ca/fr/avis-rappel/sotrovimab-pour-injection-risque-echec-therapeutique-en-raison-circulation-du-ba2-sous
2022
false
false
false
Canada
French
English
COVID-19
risk
pharmacovigilance note
treatment failure
sotrovimab
SARS-CoV-2 variants
new coronavirus variant
infusions, intravenous
sotrovimab
---
https://sante.gouv.fr//IMG/pdf/dgs-urgent_no2022-13_gsk_sotrovimab.pdf
2022
false
false
false
France
COVID-19
Product containing precisely sotrovimab 62.5 milligram/1 milliliter conventional release
solution for injection (clinical drug)
infusions, intravenous
drug information
sotrovimab
scientific and technical information
sotrovimab
---
https://ansm.sante.fr/actualites/traitement-curatif-contre-le-covid-19-un-nouvel-anticorps-monoclonal-dans-larsenal-therapeutique
2022
false
false
false
France
French
drug information
COVID-19
sotrovimab
SARS-CoV-2 variants
new coronavirus variant
adult
adolescent
infusions, intravenous
---
https://www.has-sante.fr/jcms/p_3308138/fr/xevudy-sotrovimab
https://has-sante.fr/jcms/p_3308222/fr/decision-n-2022-0001/dc/sem-du-6-janvier-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-de-la-demande-d-acces-precoce-de-la-specialite-xevudy
https://www.has-sante.fr/jcms/p_3336466/fr/decision-n2022-0148/dc/sem-du-28-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-modification-de-l-autorisation-d-acces-precoce-de-la-specialite-xevudy
2022
false
false
false
France
COVID-19
treatment outcome
adult
adolescent
Product containing precisely sotrovimab 62.5 milligram/1 milliliter conventional release
solution for injection (clinical drug)
COVID-19
risk factors
aged, 80 and over
aged
immunocompromised host
pharmacovigilance
package leaflet
summary of product characteristics
sotrovimab
evaluation of the transparency committee
sotrovimab
---
https://www.has-sante.fr/jcms/p_3344048/fr/xevudy-sotrovimab
https://has-sante.fr/jcms/p_3336466/fr/decision-n2022-0148/dc/sem-du-28-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-modification-de-l-autorisation-d-acces-precoce-de-la-specialite-xevudy
2022
false
false
false
France
French
evaluation of the transparency committee
sotrovimab
xevudy
sotrovimab
---
Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2021/76573a-fra.php
2021
false
false
false
Canada
French
English
sotrovimab
drug information
drug approval
canada
COVID-19
sotrovimab
adult
adolescent
Product containing precisely sotrovimab 62.5 milligram/1 milliliter conventional release
solution for injection (clinical drug)
infusions, intravenous
antiviral agents
coronavirus infections
antibodies, monoclonal, humanized
---
